---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-24-000064"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:26:10.629127+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports Q2 net loss $14.1M; Fast Track for IMM-1-104; initial Phase 2 data expected 2H 2024

## Summary
- Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.
- Cash $59.7M as of June 30, 2024; expected cash runway into 2H 2025.
- FDA granted Fast Track designation for IMM-1-104 in first-line pancreatic cancer.
- Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024.
- Initial PK/PD/safety data for IMM-6-415 Phase 1 expected in 2H 2024.

## SEC filing metadata
- accession: 0001790340-24-000064
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/0001790340-24-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000064/imrx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-24-000064
- JSON: https://secwatch.observer/filing/0001790340-24-000064.json
- Plain text: https://secwatch.observer/filing/0001790340-24-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.